Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2024 it was 96.5%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 96.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 96.7% | – |
See a number that looks wrong?